Free Trial
→ Buffett’s favorite chart just hit 209% – here’s what that means for gold (From Golden Portfolio) (Ad) Buy SYRE Stock  Free SYRE Stock Alerts

Spyre Therapeutics (SYRE) Financials

Spyre Therapeutics logo
$15.01 -0.06 (-0.40%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$15.01 0.00 (0.00%)
As of 05/23/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Spyre Therapeutics

Annual Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 -208 -339 -84 -66 -81 -78 -44 -27 -22 -12 -21
Consolidated Net Income / (Loss)		 -208 -339 -84 -66 -81 -78 -44 -27 -22 -11 -10
Net Income / (Loss) Continuing Operations		 -208 -339 -84 -66 -81 -78 -44 -27 -22 -11 -8.90
Total Pre-Tax Income 		-208 -339 -84 -66 -81 -78 -44 -27 -22 -11 -8.90
Total Operating Income		 -209 -242 -85 -66 -81 -80 -45 -28 -22 -11 -8.90
Total Gross Profit		 0.00 0.89 2.33 19 0.00 0.00 3.89 5.21 4.63 6.09 0.00
Total Revenue		 0.00 0.89 2.33 19 0.00 0.00 3.89 5.21 4.63 6.09 0.00
Operating Revenue		 0.00 0.89 2.33 19 0.00 0.00 3.89 5.21 4.63 6.09 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 209 243 87 84 81 80 49 33 27 17 8.90
Selling, General & Admin Expense		 46 40 29 27 22 16 13 10 8.39 5.95 2.07
Research & Development Expense		 163 220 59 57 60 65 37 23 18 11 6.83
Other Operating Expenses / (Income)		 0.00 -16 0.00 0.00 - - - - - - -
Total Other Income / (Expense), net		 0.60 -97 0.84 -0.01 0.59 2.08 1.12 0.44 0.21 0.02 0.00
Interest & Investment Income		 21 6.15 0.84 0.11 0.59 2.14 1.17 0.48 0.24 0.02 0.00
Other Income / (Expense), net		 -21 -103 0.00 -0.12 -0.01 -0.06 -0.06 -0.04 -0.04 -0.00 -
Income Tax Expense		 0.05 -0.03 -0.14 0.14 0.00 0.00 - - - - -
Basic Earnings per Share		 ($257.60) ($1,114.33) $0.00 $0.00 ($1.52) ($2.45) ($2.13) ($1.80) ($2.22) ($19.21) ($77.36)
Weighted Average Basic Shares Outstanding		 47.49M 7.34M 0.00 2.63M 53.37M 31.95M 20.82M 15.13M 9.79M 599.79K 32.86K
Diluted Earnings per Share		 ($257.60) ($1,114.33) $0.00 $0.00 ($1.52) ($2.45) ($2.13) ($1.80) ($2.22) ($19.21) ($77.36)
Weighted Average Diluted Shares Outstanding		 47.49M 7.34M 0.00 2.63M 53.37M 31.95M 20.82M 15.13M 9.79M 599.79K 32.86K
Weighted Average Basic & Diluted Shares Outstanding		 60.28M 36.15M 65.40M 65.74M 53.37M 31.95M 20.82M 15.13M 9.79M 599.79K 532.38K

Quarterly Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -45 -56 -69 -39 -44 -63 -40 -217 -18 -19 -18
Consolidated Net Income / (Loss)		 -45 -56 -69 -39 -44 -63 -40 -217 -18 -19 -18
Net Income / (Loss) Continuing Operations		 -45 -56 -69 -39 -44 -63 -40 -217 -18 -19 -18
Total Pre-Tax Income 		-45 -56 -69 -39 -44 -63 -40 -217 -18 -19 -18
Total Operating Income		 -54 -61 -55 -44 -48 -46 -18 -159 -19 -19 -19
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.69 0.20 0.17 0.17
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.69 0.20 0.17 0.17
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 54 61 55 44 48 46 18 160 19 19 19
Selling, General & Admin Expense		 12 11 11 12 13 14 8.58 12 5.23 5.08 6.95
Research & Development Expense		 42 50 45 33 35 34 24 148 14 14 12
Total Other Income / (Expense), net		 8.78 4.96 -14 5.31 3.95 -17 -22 -58 0.35 0.41 0.31
Interest & Investment Income		 6.49 5.78 5.18 5.92 4.43 4.13 1.25 0.35 0.42 0.41 0.29
Other Income / (Expense), net		 2.29 -0.82 -19 -0.61 -0.48 -21 -23 -58 -0.07 0.00 0.02
Income Tax Expense		 -0.02 0.00 0.02 0.00 0.03 - 0.00 0.01 -0.04 0.06 -0.21
Basic Earnings per Share		 ($48.50) ($1.19) $1.06 $0.59 $0.72 ($8.61) $0.86 $40.14 $0.00 $0.00 ($4.84)
Weighted Average Basic Shares Outstanding		 60.63M 47.49M 50.89M 45.32M 36.51M 7.34M 4.29M 3.82M 3.77M 0.00 3.77M
Diluted Earnings per Share		 ($48.50) ($1.19) $1.06 $0.59 $0.72 ($8.61) $0.86 $40.14 $0.00 $0.00 ($4.84)
Weighted Average Diluted Shares Outstanding		 60.63M 47.49M 50.89M 45.32M 36.51M 7.34M 4.29M 3.82M 3.77M 0.00 3.77M
Weighted Average Basic & Diluted Shares Outstanding		 60.35M 60.28M 51.43M 50.79M 40.28M 36.15M 4.05M 101.19M 65.40M 65.40M 61.51M

Annual Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -100 153 19 -75 71 -1.71 9.64 -35 18 27 -1.98
Net Cash From Operating Activities		 -157 -100 -80 -54 -76 -66 -32 -25 -19 -11 -7.34
Net Cash From Continuing Operating Activities		 -157 -100 -80 -54 -76 -66 -32 -25 -19 -11 -7.34
Net Income / (Loss) Continuing Operations		 -208 -339 -84 -66 -81 -78 -44 -27 -22 -11 -10
Consolidated Net Income / (Loss)		 -208 -339 -84 -66 -81 -78 -44 -27 -22 -11 -10
Depreciation Expense		 0.00 0.74 1.57 1.58 1.00 0.42 0.29 0.25 0.13 0.09 0.02
Amortization Expense		 -11 -2.10 0.07 0.97 0.07 -0.82 -0.59 0.08 0.10 0.00 -
Non-Cash Adjustments To Reconcile Net Income		 67 243 7.10 7.70 6.59 5.86 5.25 2.50 1.18 1.56 2.97
Changes in Operating Assets and Liabilities, net		 -4.53 -2.88 -5.07 1.83 -2.54 7.10 7.20 -0.20 1.45 -1.33 0.03
Net Cash From Investing Activities		 -353 -108 57 -23 -7.60 -1.74 -15 -23 -12 -4.01 -0.22
Net Cash From Continuing Investing Activities		 -353 -108 57 -23 -7.60 -1.74 -15 -23 -12 -4.01 -0.22
Purchase of Property, Plant & Equipment		 0.00 0.00 -0.04 -0.57 -4.28 -1.49 -0.42 -0.62 -0.21 -0.21 -0.18
Purchase of Investments		 -599 -167 -40 -133 -129 -92 -62 -64 -20 -3.77 -
Sale of Property, Plant & Equipment		 0.00 0.48 0.00 0.00 - - - - - - -
Divestitures		 0.00 18 0.00 0.00 - - - - - - -
Sale and/or Maturity of Investments		 246 40 97 111 126 92 47 42 8.45 - -
Net Cash From Financing Activities		 411 361 43 1.39 155 66 57 12 49 42 5.58
Net Cash From Continuing Financing Activities		 411 361 43 1.39 155 66 57 12 49 42 5.58
Issuance of Common Equity		 413 367 43 1.90 155 66 3.02 0.83 49 0.02 -
Other Financing Activities, net		 -1.84 -5.80 -0.42 -0.51 -0.02 -0.03 54 11 - - -
Other Net Changes in Cash		 -0.00 0.03 -0.11 - 0.05 - - - - - -

Quarterly Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -41 18 26 -182 39 97 -145 200 0.14 -4.10 1.24
Net Cash From Operating Activities		 -41 -37 -29 -62 -29 -31 -35 -17 -18 -18 -15
Net Cash From Continuing Operating Activities		 -41 -37 -29 -62 -29 -31 -35 -17 -18 -18 -15
Net Income / (Loss) Continuing Operations		 -45 -56 -69 -39 -44 -63 -40 -217 -18 -19 -18
Consolidated Net Income / (Loss)		 -45 -56 -69 -39 -44 -63 -40 -217 -18 -19 -18
Amortization Expense		 -2.64 -2.42 -3.00 -3.56 -2.42 -1.71 -0.49 0.04 0.06 -0.05 -0.05
Non-Cash Adjustments To Reconcile Net Income		 6.99 11 32 9.31 14 36 12 194 1.51 1.36 1.39
Changes in Operating Assets and Liabilities, net		 -0.57 11 10 -29 3.47 -1.86 -5.92 6.07 -1.17 -1.02 1.43
Net Cash From Investing Activities		 -0.06 -171 43 -121 -105 -35 -98 6.76 18 14 16
Net Cash From Continuing Investing Activities		 -0.06 -171 43 -121 -105 -35 -98 6.76 18 14 16
Purchase of Investments		 -71 -233 -35 -178 -153 -54 -113 - 0.00 -4.50 -7.25
Sale and/or Maturity of Investments		 71 63 78 58 48 19 - 3.25 18 19 24
Net Cash From Financing Activities		 0.13 226 13 0.36 172 164 -13 210 0.01 -0.01 -0.13
Net Cash From Continuing Financing Activities		 0.13 226 13 0.36 172 164 -13 210 0.01 -0.01 -0.13
Issuance of Common Equity		 0.34 395 13 0.50 4.39 367 0.11 - 0.02 - -0.07
Other Financing Activities, net		 -0.21 -0.33 -0.08 - -1.43 -5.79 - -0.01 -0.01 -0.01 -0.06
Other Net Changes in Cash		 0.00 - - - -0.00 - - 0.01 0.01 0.05 -

Annual Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 608 342 71 110 162 83 78 56 67 39
Total Current Assets		 608 342 62 99 150 75 77 55 66 38
Cash & Equivalents		 89 189 35 15 90 19 22 13 48 29
Short-Term Investments		 514 150 21 78 56 53 52 37 16 3.77
Prepaid Expenses		 5.39 2.25 6.17 4.95 3.52 2.56 2.16 1.61 1.71 0.91
Plant, Property, & Equipment, net		 0.00 0.00 3.22 4.55 5.64 2.39 1.02 0.85 0.60 0.35
Total Noncurrent Assets		 0.01 0.33 5.67 6.49 6.19 6.29 0.05 0.23 0.04 0.02
Other Noncurrent Operating Assets		 0.01 0.33 5.67 6.49 6.19 6.29 0.05 0.23 0.04 0.02
Total Liabilities & Shareholders' Equity		 608 342 71 110 162 83 78 56 67 39
Total Liabilities		 91 73 21 26 22 23 10 5.74 4.10 2.55
Total Current Liabilities		 54 32 15 20 16 18 10 5.63 3.97 2.52
Accounts Payable		 1.27 17 0.68 3.32 2.25 3.15 0.66 0.39 0.17 0.18
Accrued Expenses		 28 13 13 14 14 15 9.58 5.22 3.73 2.35
Other Current Liabilities		 25 1.39 0.63 0.44 0.32 0.35 - - - -
Total Noncurrent Liabilities		 37 41 6.18 5.84 5.34 4.74 0.07 0.11 0.13 0.03
Other Noncurrent Operating Liabilities		 37 41 4.00 4.61 5.13 4.71 - - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 85 0.00 - - - - - - 58
Total Equity & Noncontrolling Interests		 518 184 50 84 140 60 67 50 63 -22
Total Preferred & Common Equity		 518 184 50 84 140 60 67 50 63 -22
Preferred Stock		 156 185 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 362 -0.91 50 84 140 60 67 50 63 -22
Common Stock		 1,334 763 476 426 416 255 184 123 108 1.37
Retained Earnings		 -972 -764 -426 -342 -276 -195 -117 -73 -45 -24
Accumulated Other Comprehensive Income / (Loss)		 0.18 0.30 -0.05 -0.02 0.01 0.05 -0.03 -0.10 -0.00 -0.00

Quarterly Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 570 421 436 488 207 244 52 92
Total Current Assets		 570 421 436 487 206 240 44 82
Cash & Equivalents		 48 72 45 228 91 235 35 39
Short-Term Investments		 516 343 381 257 113 0.00 3.24 35
Prepaid Expenses		 4.95 6.85 9.74 2.63 2.19 2.88 5.57 7.87
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 3.42 3.56
Total Noncurrent Assets		 0.01 0.01 0.33 0.33 1.32 3.64 4.65 5.79
Other Noncurrent Operating Assets		 0.01 0.01 0.33 0.33 1.32 3.64 4.65 5.79
Total Liabilities & Shareholders' Equity		 570 421 436 488 207 244 52 92
Total Liabilities		 87 94 62 82 66 254 19 24
Total Current Liabilities		 71 58 22 43 45 232 13 18
Accounts Payable		 6.24 20 14 19 22 24 2.06 4.18
Accrued Expenses		 22 13 5.68 22 16 28 9.67 12
Other Current Liabilities		 43 25 2.64 2.59 7.51 179 0.61 0.59
Total Noncurrent Liabilities		 16 36 40 39 21 21 6.16 6.33
Other Noncurrent Operating Liabilities		 16 36 40 39 21 0.00 3.82 4.16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 483 327 374 152 -245 -207 34 68
Total Preferred & Common Equity		 483 327 374 152 -245 -207 34 68
Preferred Stock		 156 156 156 185 0.00 0.00 0.00 0.00
Total Common Equity		 327 172 219 -33 -245 -207 34 68
Common Stock		 1,343 1,086 1,066 776 456 454 478 475
Retained Earnings		 -1,017 -916 -847 -808 -701 -661 -444 -407
Accumulated Other Comprehensive Income / (Loss)		 0.68 1.46 -0.55 -0.36 -0.13 0.01 -0.01 -0.18

Annual Metrics And Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% -61.96% -87.57% 0.00% 0.00% -100.00% -25.30% 12.47% -23.94% 0.00% 0.00%
EBITDA Growth		 30.50% -316.53% -31.51% 21.38% 0.47% -76.34% -67.26% -26.19% -93.38% -26.35% 0.00%
EBIT Growth		 33.54% -306.89% -28.90% 19.29% -1.35% -76.62% -64.23% -26.32% -93.89% -27.10% 0.00%
NOPAT Growth		 13.92% -185.80% -29.14% 19.43% -1.43% -76.70% -64.27% -26.34% -93.60% -27.08% 0.00%
Net Income Growth		 38.60% -304.21% -27.38% 18.66% -3.37% -76.45% -62.83% -25.52% -92.10% -9.16% 0.00%
EPS Growth		 76.88% 0.00% -27.38% 18.66% 37.96% -15.02% -18.33% 18.92% 88.44% 75.17% 0.00%
Operating Cash Flow Growth		 -57.55% -24.66% -49.20% 29.11% -15.35% -104.06% -30.79% -30.65% -71.55% -49.72% 0.00%
Free Cash Flow Firm Growth		 -25.99% -65.28% -46.74% 31.34% -21.86% -108.46% -23.77% -66.87% -9.46% 0.00% 0.00%
Invested Capital Growth		 -20.62% -1,207.92% 41.05% -47.28% 47.39% -68.79% -4,806.71% 136.88% -113.52% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% -15.94% -59.88% 24.14% 0.00% 0.00% -27.61% 4.75% -6.81% 0.00% 0.00%
EBITDA Q/Q Growth		 1.84% -16.95% 1.38% 4.10% -0.47% -8.54% -24.31% -4.21% -7.65% 0.00% 0.00%
EBIT Q/Q Growth		 2.23% -16.22% 1.51% 3.38% -1.03% -8.95% -23.60% -4.05% -7.77% 0.00% 0.00%
NOPAT Q/Q Growth		 -7.94% -12.41% 1.49% 3.43% -1.08% -8.96% -23.59% -4.08% -7.59% 0.00% 0.00%
Net Income Q/Q Growth		 3.20% -15.07% 1.90% 3.33% -1.53% -9.21% -23.42% -3.81% -7.41% 0.00% 0.00%
EPS Q/Q Growth		 -6,004.27% -1,525.10% 1.90% 3.33% -18.75% -0.41% -13.90% -141.00% 84.71% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -4.07% -14.82% 1.39% -4.14% -1.12% -16.07% -4.30% -5.24% -25.38% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -19.13% -9.67% 2.10% -5.05% -1.71% -17.60% 0.96% -8.88% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 1.79% -14.23% 11.68% 11.37% -68.21% -33.50% -620.76% 220.16% -313.76% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% -39,087.70% -3,569.94% -337.38% 0.00% 0.00% -1,178.50% -526.30% -469.08% -184.49% 0.00%
Operating Margin		 0.00% -27,347.97% -3,640.23% -350.33% 0.00% 0.00% -1,169.32% -531.72% -473.34% -185.95% 0.00%
EBIT Margin		 0.00% -38,934.88% -3,640.23% -350.98% 0.00% 0.00% -1,170.78% -532.53% -474.11% -185.98% 0.00%
Profit (Net Income) Margin		 0.00% -38,238.15% -3,598.75% -351.14% 0.00% 0.00% -1,140.64% -523.27% -468.84% -185.62% 0.00%
Tax Burden Percent		 100.02% 99.99% 99.84% 100.21% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 116.22%
Interest Burden Percent		 90.70% 98.22% 99.02% 99.83% 99.27% 97.33% 97.43% 98.26% 98.89% 99.81% 99.99%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,186.40% -529.98% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,173.21% -509.60% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,142.60% 467.41% 0.00%
Return on Equity (ROE)		 -52.91% -212.49% -124.87% -58.81% -80.93% -122.74% -75.32% -48.08% -43.80% -62.57% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13,373.29% 0.00% -729.98% 0.00%
Operating Return on Assets (OROA)		 0.00% -167.05% -93.64% -48.44% 0.00% 0.00% -68.03% -45.02% -41.51% -29.28% 0.00%
Return on Assets (ROA)		 0.00% -164.06% -92.58% -48.46% 0.00% 0.00% -66.28% -44.24% -41.05% -29.22% 0.00%
Return on Common Equity (ROCE)		 -24.29% -32.91% -124.87% -58.81% -80.93% -122.74% -75.32% -48.08% -18.02% 38.49% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -40.17% -184.11% -166.61% -78.39% -57.85% -130.25% -65.77% -54.11% -34.46% 50.86% 0.00%
Net Operating Profit after Tax (NOPAT)		 -146 -170 -59 -46 -57 -56 -32 -19 -15 -7.92 -6.23
NOPAT Margin		 0.00% -19,143.58% -2,548.16% -245.23% 0.00% 0.00% -818.52% -372.20% -331.34% -130.16% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -13.16% -85.66% -32.88% -16.60% -21.89% -30.09% -20.10% -13.85% -13.19% -20.38% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -28.20% -92.17% -117.97% - - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 4,508.58% 1,225.03% 145.79% 0.00% 0.00% 324.90% 193.39% 181.31% 97.73% 0.00%
R&D to Revenue		 0.00% 24,795.94% 2,515.20% 304.55% 0.00% 0.00% 944.42% 438.33% 392.03% 188.22% 0.00%
Operating Expenses to Revenue		 0.00% 27,447.97% 3,740.23% 450.33% 0.00% 0.00% 1,269.32% 631.72% 573.34% 285.95% 0.00%
Earnings before Interest and Taxes (EBIT)		 -229 -345 -85 -66 -81 -80 -46 -28 -22 -11 -8.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -241 -346 -83 -63 -80 -81 -46 -27 -22 -11 -8.89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.31 0.00 13.75 69.77 67.45 92.15 66.54 44.72 23.20 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.31 0.00 13.75 69.77 67.45 92.15 66.54 44.72 23.20 0.00 0.00
Price to Revenue (P/Rev)		 0.00 98.34 297.06 312.54 0.00 0.00 1,154.04 432.50 315.60 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14,770.78 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 19.57 273.14 307.57 0.00 0.00 1,134.87 422.83 301.88 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.20 -1.24 -1.11 -1.07 -1.09 -1.15 -1.06 -1.00 -0.97 -0.92 0.00
Leverage Ratio		 1.21 1.30 1.35 1.21 1.22 1.26 1.14 1.09 1.07 1.07 0.00
Compound Leverage Factor		 1.10 1.27 1.34 1.21 1.22 1.23 1.11 1.07 1.06 1.07 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 30.09% 68.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 31.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 161.51% 0.00%
Common Equity to Total Capital		 69.91% -0.34% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -61.51% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.53 -4.66 8.45 129.94 256.69 138.12 258.13 233.02 213.07 0.00 0.00
Noncontrolling Interest Sharing Ratio		 54.08% 84.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 58.86% 161.51% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.26 10.68 4.25 4.91 9.11 4.06 7.49 9.77 16.75 15.17 0.00
Quick Ratio		 11.16 10.61 3.83 4.66 8.90 3.92 7.28 8.94 16.02 13.10 0.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -131 -104 -63 -43 -63 -51 -25 -20 -12 -11 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% -210,905.26% -9,374.52% -1,770.44% -4,402.95% -7,628.67% -3,976.58% -8,886.79% -5,279.81% -4,052.49%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.03 0.14 0.00 0.00 0.06 0.08 0.09 0.16 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.60 3.68 0.00 0.00 4.15 7.16 9.77 17.49 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -85 -71 -5.41 -9.17 -6.23 -12 -7.01 0.15 -0.40 2.99 0.00
Invested Capital Turnover		 0.00 -0.02 -0.32 -2.43 0.00 0.00 -1.13 -40.82 3.58 4.07 0.00
Increase / (Decrease) in Invested Capital		 -15 -65 3.77 -2.94 5.61 -4.82 -7.16 0.55 -3.39 2.99 0.00
Enterprise Value (EV)		 750 17 636 5,764 9,285 5,464 4,412 2,201 1,397 0.00 0.00
Market Capitalization		 1,197 87 692 5,857 9,432 5,536 4,487 2,251 1,461 0.00 0.00
Book Value per Share		 $7.04 ($0.23) $0.82 $1.70 $2.92 $2.07 $2.81 $3.02 $4.69 ($37.02) $0.00
Tangible Book Value per Share		 $7.04 ($0.23) $0.82 $1.70 $2.92 $2.07 $2.81 $3.02 $4.69 ($37.02) $0.00
Total Capital		 518 269 50 84 140 60 67 50 63 36 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -603 -339 -56 -93 -146 -72 -75 -50 -64 -33 0.00
Capital Expenditures (CapEx)		 0.00 -0.48 0.04 0.57 4.28 1.49 0.42 0.62 0.21 0.21 0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -49 -30 -8.11 -14 -13 -16 -8.08 -0.94 -1.04 2.62 0.00
Debt-free Net Working Capital (DFNWC)		 554 310 48 79 133 56 66 49 62 36 0.00
Net Working Capital (NWC)		 554 310 48 79 133 56 66 49 62 36 0.00
Net Nonoperating Expense (NNE)		 62 169 24 20 24 22 13 7.86 6.36 3.37 4.11
Net Nonoperating Obligations (NNO)		 -603 -339 -56 -93 -146 -72 -74 -50 -63 -33 0.00
Total Depreciation and Amortization (D&A)		 -11 -1.35 1.64 2.55 1.07 -0.40 -0.30 0.32 0.23 0.09 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -3,355.19% -348.18% -76.74% 0.00% 0.00% -207.84% -18.00% -22.54% 43.07% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 34,937.92% 2,043.88% 420.23% 0.00% 0.00% 1,708.64% 948.36% 1,349.59% 587.72% 0.00%
Net Working Capital to Revenue		 0.00% 34,937.92% 2,043.88% 420.23% 0.00% 0.00% 1,708.64% 948.36% 1,349.59% 587.72% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($257.60) $0.00 ($0.99) ($1.00) ($1.52) ($2.45) ($2.13) ($1.80) $0.00 $0.00 ($77.36)
Adjusted Weighted Average Basic Shares Outstanding		 47.49M 0.00 84.28M 49.36M 48.02M 29.09M 28.82M 16.72M 13.45M 599.79K 32.86K
Adjusted Diluted Earnings per Share		 ($257.60) $0.00 ($0.99) ($1.00) ($1.52) ($2.45) ($2.13) ($1.80) $0.00 $0.00 ($77.36)
Adjusted Weighted Average Diluted Shares Outstanding		 47.49M 0.00 84.28M 49.36M 48.02M 29.09M 28.82M 16.72M 13.45M 599.79K 32.86K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.00) ($1.52) ($2.45) ($2.13) ($1.80) $0.00 $0.00 ($77.36)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.28M 0.00 65.40M 65.74M 53.37M 31.95M 20.82M 15.13M 13.45M 599.79K 532.38K
Normalized Net Operating Profit after Tax (NOPAT)		 -146 -170 -59 -46 -57 -56 -32 -19 -15 -7.92 -6.23
Normalized NOPAT Margin		 0.00% -19,143.58% -2,548.16% -245.23% 0.00% 0.00% -818.52% -372.20% -331.34% -130.16% 0.00%
Pre Tax Income Margin		 0.00% -38,241.08% -3,604.59% -350.39% 0.00% 0.00% -1,140.64% -523.27% -468.84% -185.62% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.95% 0.00%

Quarterly Metrics And Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% -100.00% 0.00% -100.00% 10.08% -85.46% -95.39% -87.56%
EBITDA Growth		 -6.40% 6.55% -84.48% 77.74% -174.88% -266.64% -127.65% -887.33% 23.05% 3.78% 6.96%
EBIT Growth		 -6.27% 7.78% -79.41% 79.41% -155.63% -251.27% -120.78% -869.86% 22.86% 6.34% 7.81%
NOPAT Growth		 -12.13% -33.41% -202.08% 72.28% -154.04% -139.61% 2.23% -610.19% 23.06% 6.26% 7.58%
Net Income Growth		 -2.09% 10.90% -72.11% 82.11% -138.07% -235.67% -119.96% -872.45% 24.61% 7.94% 10.21%
EPS Growth		 17.21% 86.18% 23.26% -98.53% 0.00% 0.00% 117.77% -872.45% 24.61% 7.94% 10.21%
Operating Cash Flow Growth		 -43.63% -19.86% 14.96% -274.02% -61.86% -71.09% -129.61% 19.49% 32.86% 5.85% 11.36%
Free Cash Flow Firm Growth		 -184.16% -185.34% -132.22% -286.09% 403.77% 293.03% 347.42% 629.98% 10.40% -51.15% -129.55%
Invested Capital Growth		 -4.11% -20.62% -40.30% 77.20% -1,536.28% -1,207.92% -911.21% -5,053.74% 4.62% 41.05% 40.84%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 247.47% 17.86% -3.45% -72.16%
EBITDA Q/Q Growth		 16.39% 16.46% -59.76% 4.66% 26.56% -64.93% 80.72% -1,077.11% 2.09% -2.40% 16.38%
EBIT Q/Q Growth		 17.38% 16.34% -65.77% 7.25% 28.30% -62.75% 80.98% -1,051.73% 1.51% -2.30% 16.45%
NOPAT Q/Q Growth		 12.55% -10.58% -25.47% 7.59% -4.05% -150.39% 88.49% -746.78% 1.86% -2.17% 16.36%
Net Income Q/Q Growth		 20.47% 18.44% -77.74% 11.45% 30.58% -57.53% 81.52% -1,078.38% 2.13% -3.22% 18.32%
EPS Q/Q Growth		 -3,975.63% -212.26% 223.26% 149.17% 107.86% -1,101.16% 101.51% -1,078.38% 2.13% -3.22% 18.32%
Operating Cash Flow Q/Q Growth		 -10.20% -26.44% 52.74% -118.09% 8.04% 10.29% -107.88% 5.62% 2.79% -20.39% 27.11%
Free Cash Flow Firm Q/Q Growth		 -21.04% -104.57% 93.27% -605.41% 22.74% -22.77% -61.15% 925.03% 22.01% 1.01% 16.79%
Invested Capital Q/Q Growth		 3.60% 1.79% -68.26% 34.64% -11.68% -14.23% 72.66% -4,591.34% 10.73% 11.68% -39.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31,544.19% -9,311.62% -11,204.17% -10,563.79%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -23,146.22% -9,497.98% -11,405.95% -10,778.74%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31,602.33% -9,534.34% -11,405.36% -10,764.94%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31,552.47% -9,304.04% -11,203.57% -10,479.31%
Tax Burden Percent		 99.97% 100.00% 100.03% 100.00% 100.07% 100.00% 100.01% 100.00% 99.81% 100.34% 98.87%
Interest Burden Percent		 87.34% 90.69% 93.01% 86.77% 90.82% 93.87% 96.98% 99.84% 97.78% 97.90% 98.46%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -47.04% -52.91% -91.62% -102.09% -165.81% -212.49% -281.41% -735.54% -163.26% -124.87% -100.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -221.61% -163.80% -293.40% -566.48%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -221.26% -159.84% -288.21% -551.45%
Return on Common Equity (ROCE)		 -15.58% -24.29% 14.42% -3.14% -0.38% -32.91% 239.16% 1,222.86% -163.26% -124.87% -100.73%
Return on Equity Simple (ROE_SIMPLE)		 -43.29% 0.00% -65.64% -49.68% -239.20% 0.00% 119.98% 131.44% -231.19% 0.00% -126.47%
Net Operating Profit after Tax (NOPAT)		 -37 -43 -39 -31 -33 -32 -13 -111 -13 -13 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16,202.35% -6,648.59% -7,984.17% -7,545.11%
Net Nonoperating Expense Percent (NNEP)		 -1.39% -2.85% -9.79% -2.47% -3.98% -15.72% -19.67% -69.27% -10.00% -7.27% -5.49%
Return On Investment Capital (ROIC_SIMPLE)		 -7.77% -8.28% - - - -17.47% - - - -26.66% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,753.20% 2,640.40% 3,023.21% 3,995.40%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21,493.02% 6,957.58% 8,482.74% 6,883.33%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23,246.22% 9,597.98% 11,505.95% 10,878.74%
Earnings before Interest and Taxes (EBIT)		 -51 -62 -74 -45 -48 -67 -41 -217 -19 -19 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -64 -77 -48 -51 -69 -42 -217 -18 -19 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.98 3.31 8.71 4.33 0.00 0.00 0.00 0.00 14.09 13.75 11.91
Price to Tangible Book Value (P/TBV)		 2.98 3.31 8.71 4.33 0.00 0.00 0.00 0.00 14.09 13.75 11.91
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 1,993.03 98.34 1,176.10 599.77 406.97 297.06 138.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1,925.72 19.57 1,350.21 568.79 373.94 273.14 125.88
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.86 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.18 -1.20 -1.32 -1.76 -1.19 -1.24 -1.33 -4.11 -1.10 -1.11 -1.10
Leverage Ratio		 1.19 1.21 1.34 1.87 1.23 1.30 1.43 4.73 1.42 1.35 1.30
Compound Leverage Factor		 1.04 1.10 1.25 1.62 1.12 1.22 1.38 4.72 1.39 1.32 1.28
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 32.29% 30.09% 47.59% 41.62% 45.59% 68.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 62.47% 31.48% 273.18% -1,964.19% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 67.71% 69.91% 52.41% 58.38% -8.05% -0.34% -173.18% 2,064.19% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.95 6.44 6.97 7.29 8.49 -1.98 6.89 -4.96 2.84 11.49 14.12
Noncontrolling Interest Sharing Ratio		 66.89% 54.08% 115.74% 96.93% 99.77% 84.51% 184.99% 266.25% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.06 11.26 7.32 19.70 11.38 10.68 4.59 1.03 3.51 4.25 4.65
Quick Ratio		 7.99 11.16 7.20 19.26 11.32 10.61 4.54 1.02 3.07 3.83 4.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -34 -28 -14 -206 41 33 43 111 -13 -17 -17
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,506,800.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.03 0.05
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.30 0.60 1.37
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -82 -85 -87 -52 -79 -71 -62 -226 -4.83 -5.41 -6.12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.03 -0.01 -0.24 -0.32 -0.71
Increase / (Decrease) in Invested Capital		 -3.24 -15 -25 175 -74 -65 -56 -222 0.23 3.77 4.23
Enterprise Value (EV)		 564 750 1,235 677 1,325 17 1,423 698 436 636 731
Market Capitalization		 973 1,197 1,494 947 1,371 87 1,240 737 474 692 804
Book Value per Share		 $5.42 $7.04 $3.38 $5.43 ($0.89) ($0.23) ($2.43) ($3.17) $0.51 $0.82 $1.10
Tangible Book Value per Share		 $5.42 $7.04 $3.38 $5.43 ($0.89) ($0.23) ($2.43) ($3.17) $0.51 $0.82 $1.10
Total Capital		 483 518 327 374 406 269 142 -10 34 50 68
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -565 -603 -414 -426 -485 -339 -204 -235 -38 -56 -74
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -66 -49 -51 -12 -40 -30 -43 -228 -6.74 -8.11 -9.14
Debt-free Net Working Capital (DFNWC)		 499 554 364 414 444 310 161 7.65 32 48 65
Net Working Capital (NWC)		 499 554 364 414 444 310 161 7.65 32 48 65
Net Nonoperating Expense (NNE)		 7.28 13 30 7.93 10 31 27 106 5.26 5.41 5.11
Net Nonoperating Obligations (NNO)		 -565 -603 -414 -426 -485 -339 -204 -216 -38 -56 -74
Total Depreciation and Amortization (D&A)		 -2.64 -2.42 -3.00 -3.56 -2.42 -1.71 -0.49 0.40 0.44 0.34 0.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -5,840.99% -3,355.19% -4,034.35% -18,542.83% -578.54% -348.18% -157.36%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 64,601.02% 34,937.92% 15,282.45% 623.13% 2,724.29% 2,043.88% 1,111.82%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 64,601.02% 34,937.92% 15,282.45% 623.13% 2,724.29% 2,043.88% 1,111.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($48.50) ($1.19) $1.06 $0.59 $0.72 ($8.61) ($9.34) ($2.27) ($0.20) $0.00 ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 60.63M 47.49M 50.89M 45.32M 36.51M 7.34M 4.29M 95.57M 94.26M 0.00 94.20M
Adjusted Diluted Earnings per Share		 ($48.50) ($1.19) $1.06 $0.59 $0.72 ($8.61) ($9.34) ($2.27) ($0.20) $0.00 ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding		 60.63M 47.49M 50.89M 45.32M 36.51M 7.34M 4.29M 95.57M 94.26M 0.00 94.20M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.19) $0.00 $0.00 $0.00 ($8.61) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.35M 60.28M 51.43M 50.79M 40.28M 36.15M 4.05M 101.19M 65.40M 65.40M 61.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -37 -43 -39 -31 -33 -32 -13 -111 -13 -13 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16,202.35% -6,648.59% -7,984.17% -7,545.11%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31,551.45% -9,322.22% -11,165.48% -10,599.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Spyre Therapeutics' Financials

When does Spyre Therapeutics's financial year end?

According to the most recent income statement we have on file, Spyre Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Spyre Therapeutics' net income changed over the last 10 years?

Spyre Therapeutics' net income appears to be on an upward trend, with a most recent value of -$208.02 million in 2024, rising from -$10.35 million in 2014. The previous period was -$338.79 million in 2023. See Spyre Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Spyre Therapeutics's operating income?
Spyre Therapeutics's total operating income in 2024 was -$208.57 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $208.57 million
How has Spyre Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Spyre Therapeutics' total revenue changed from $0.00 in 2014 to $0.00 in 2024, a change of 0.0%.

How much debt does Spyre Therapeutics have?

Spyre Therapeutics' total liabilities were at $90.68 million at the end of 2024, a 23.7% increase from 2023, and a 3,456.1% increase since 2015.

How much cash does Spyre Therapeutics have?

In the past 9 years, Spyre Therapeutics' cash and equivalents has ranged from $12.82 million in 2017 to $188.89 million in 2023, and is currently $89.42 million as of their latest financial filing in 2024.

How has Spyre Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Spyre Therapeutics' book value per share changed from 0.00 in 2014 to 7.04 in 2024, a change of 703.8%.


Related Companies

This page (NASDAQ:SYRE) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored